Form 10-Q INOVIO PHARMACEUTICALS, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Inovio's (INO) DNA Technology Platform Further Validated with Latest Qtr. Results - Stifel
November 9, 2015 2:46 PM ESTStifel affirms its Buy rating and $19 price target on Inovio (Nasdaq: INO) following the company's Q3 report and update issued earlier Monday.
Analyst Thomas Shrader, PhD, CFA, noted that EPS of $0.07 was flat with consensus estimates and revenue was driven by... More
Inovio Pharma (INO) Swings to Q3 Profit
November 9, 2015 6:28 AM ESTInovio Pharma (NASDAQ: INO) reported Q3 EPS of $0.07, versus ($0.12) reported last year. Revenue for the quarter came in at $24.18 million, versus $1.84 million reported last year.
For earnings history and earnings-related data on Inovio Pharma (INO) click here.
... More